Celltrion Recovers With High-Margin US Sales
Company Files For Donepezil Patch With Korean Ministry of Food and Drug Safety
South Korea’s Celltrion has delivered a strong second quarter on the back of high-margin US sales, as its Truxima rituximab biosimilar recovered. The company is on track to launch at least one biosimilar every year by 2030. Meanwhile, the company and partner Icure have filed a donepezil patch with the Korean Ministry of Food and Drug Safety.
